icrf 193 has been researched along with daunorubicin in 3 studies
| Studies (icrf 193) | Trials (icrf 193) | Recent Studies (post-2010) (icrf 193) | Studies (daunorubicin) | Trials (daunorubicin) | Recent Studies (post-2010) (daunorubicin) |
|---|---|---|---|---|---|
| 155 | 0 | 30 | 8,239 | 886 | 1,310 |
| Protein | Taxonomy | icrf 193 (IC50) | daunorubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 1.9 | |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.047 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.22 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Austin, CA; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Korábečný, J; Kubeš, J; Kučera, T; Melnikova, I; Nováková, L; Roh, J; Šimůnek, T; Skalická, V; Škoda, J; Štěrba, M | 1 |
| Adamcová, M; Holečková, M; Jirkovská, A; Karabanovich, G; Kocúrová-Lengvarská, J; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
3 other study(ies) available for icrf 193 and daunorubicin
| Article | Year |
|---|---|
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Diketopiperazines; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myocytes, Cardiac; Piperazines; Protein Binding; Rats, Wistar; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Chronic Disease; Daunorubicin; Diketopiperazines; Disease Models, Animal; DNA Damage; Fibrosis; HL-60 Cells; Humans; Male; Myocytes, Cardiac; Prodrugs; Rabbits; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |